Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsSanford Health Plan Actimmune Prior Auth | OpenPay…
    Ask Trek AI about this page
    CurrentSanford Health PlanPolicy 26213

    Actimmune (S) Prior Authorization Criteria

    Customize your policy alerts

    Sign up for sanford health plan Policy 26213 alerts

    Get alerted when Policy 26213 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization coverage for Actimmune (interferon gamma-1b) injection for chronic granulomatous disease or severe malignant osteopetrosis when the required diagnosis is documented.

    Policy Summary
    PayerSanford Health Plan
    PolicyActimmune (S) Prior Authorization Criteria
    Policy CodePolicy 26213
    Change TypeNo material change
    Effective DateSep 1, 2026
    Next Review DateN/A
    Key ActionSubmit documentation confirming chronic granulomatous disease or severe malignant osteopetrosis.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2Covered diagnoses
    12 monthsCoverage duration
    1Affected products
    Not requiredPrerequisite Part D drug

    Covered Products and Medical Necessity Criteria

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Covered indications and medical-necessity pathways

    Covered when the requested product is used for one of the listed medically accepted indications and the applicable disease, laboratory, molecular, age, specialist, prior-treatment, and combination-therapy requirements are met.

    Actimmune: Chronic granulomatous disease or severe malignant osteopetrosis.
    Pulmonary and respiratory therapies: Adempas: symptomatic PAH confirmed by right-heart catheterization or current PAH therapy, or symptomatic/inoperable or persistent/recurrent CTEPH or current CTEPH therapy; arformoterol: COPD maintenance treatment; Bronchitol: cystic fibrosis after a passed tolerance test; Arikayce: MAC lung disease as part of combination antibacterial therapy after failure to achieve at least two negative sputum cultures following at least 6 months of multidrug therapy; roflumilast: COPD with qualifying exacerbations and two prior COPD therapies; Esbriet: IPF established by exclusion of other ILD causes and qualifying HRCT/biopsy findings.
    Oncology and hematology therapies: Covered indications include the product-specific cancers and blood disorders documented in the policy, including SEGA/TSC, RCC, pNET and other NETs, breast cancer, prostate cancer, NSCLC, urothelial carcinoma with FGFR3 alteration, CML, AML, MCL, CLL/SLL, melanoma or colorectal cancer with required BRAF mutations, medullary thyroid cancer, basal cell carcinoma, renal cell carcinoma, colorectal cancer, RET-, ROS1-, HER2-, KRAS-, IDH1/IDH2-, BRCA-, or other molecularly defined tumors, and metastatic or advanced disease where specified. Combination regimens, prior systemic therapy, disease progression, or mutation testing apply by product.
    Neurologic and seizure therapies: Dalfampridine: MS with walking difficulty and EDSS ≤7 or no wheelchair restriction; Aimovig or Emgality: qualifying episodic or chronic migraine or episodic cluster headache; Austedo: Huntington chorea or tardive dyskinesia; Briviact: partial-onset seizures in a patient at least 1 month old; Diacomit: Dravet-associated seizures with clobazam, weight ≥7 kg, and age ≥6 months; Epidiolex or Fintepla: qualifying LGS, Dravet, or TSC seizures; Evrysdi: SMA type I, II, or III with required SMN1/SMN2, respiratory, motor, and gene-therapy criteria; Inbrija: Parkinson disease with intermittent OFF episodes while receiving carbidopa/levodopa; Igalmi: acute agitation associated with schizophrenia or bipolar disorder; growth hormone products and Increlex: qualifying growth or IGF-1 deficiency criteria.
    Immunology, rheumatology, and dermatology: Avtozma, Cosentyx, Cosentyx IV, Enbrel, Humira, and related biologics are covered for the specified active RA, PJIA, PsA, plaque psoriasis, AS, nr-axSpA, ERA, HS, inflammatory bowel disease, uveitis, GCA, SJIA, or SSc-ILD indications when the applicable severity, objective inflammation, topical/NSAID/conventional-therapy, and specialist requirements are met. Benlysta is covered for active SLE or lupus nephritis with standard-of-care therapy and age ≥5 years. Dupixent, Ebglyss, Eucrisa, Fasenra, and related therapies are covered for their listed asthma, atopic dermatitis, CRSwNP, EoE, COPD, EGPA, HES, urticaria, or other specified inflammatory indications.
    Rare disease and metabolic therapies: Prolastin-c: congenital AAT deficiency with emphysema, qualifying genotype, and pretreatment serum AAT <11 µM/L; Ayvakit: qualifying GIST, AdvSM, or ISM with platelet count ≥50 × 10^9/L; Cerdelga: type 1 Gaucher disease in an adult with FDA-cleared CYP2D6 EM, IM, or PM status; Cholbam: qualifying bile-acid synthesis or peroxisomal disorder; Ctexli: CYP27A1-confirmed cerebrotendinous xanthomatosis; Fabrazyme: confirmed Fabry disease at age ≥2 years; Empaveli: PNH, C3G, or primary IC-MPGN; deferasirox: transfusional iron overload, MDS, or NTDT; and other product-specific inherited, metabolic, or immune disorders.
    Other covered specialty products: Coverage also includes Cialis/tadalafil for a medically accepted indication with required alpha-blocker or 5-alpha-reductase-inhibitor exception; Ciclopirox for confirmed qualifying onychomycosis; Cinryze for HAE prophylaxis; Cablivi for acquired TTP; Pyrimethamine for qualifying toxoplasmosis; Metyrosine for pheochromocytoma; Doptelet for procedure-related thrombocytopenia or ITP; Procrit for specified anemia indications; Gamastan when IM immune globulin is needed for immunization; Fentanyl oral transmucosal therapy for breakthrough cancer pain in an opioid-tolerant patient; and other listed specialty-drug indications when all product-specific criteria are met.
    Continuation of previously authorized therapy may be approved when the underlying indication remains supported and any product-specific response, monitoring, combination, or treatment restrictions remain satisfied.

    Exclusions, contraindications, and non-covered uses

    The following uses or combinations are excluded from coverage or are not authorized under the policy.

    Cialis exclusion: Concurrent use of nitrates excludes Cialis/tadalafil coverage.
    Cinryze exclusion: Cinryze must not be used with another approved treatment for prophylaxis against HAE attacks.
    Ciclopirox restriction: Ciclopirox is not covered under these criteria when the onychomycosis involves the lunula or nail matrix.
    Pyrimethamine exclusion: Treatment or prophylaxis of malaria with pyrimethamine is not authorized and will not be approved.
    Metyrosine exclusion:

    Initial Authorization Criteria

    Initial therapy criteria

    Initial therapy is covered when the applicable product-specific pathway is satisfied. Each pathway requires all listed elements; alternative indications within a product are separated by OR logic.

    Actimmune and core specialty products: Actimmune: CGD or SMO. Adempas: qualifying PAH or CTEPH with symptoms and right-heart-catheterization confirmation or current disease therapy, plus pulmonologist or cardiologist involvement. Afinitor: qualifying SEGA, RCC, pNET, TSC-associated angiomyolipoma, HR-positive/HER2-negative breast cancer, or progressive GI/lung NET; required SUTENT/NEXAVAR or FEMARA/ARIMIDEX failure, contraindication, or intolerance applies where specified. Afinitor Disperz: SEGA requiring intervention or TSC-associated partial-onset seizures, with age ≥1 year for SEGA or ≥2 years for seizures. Aimovig: episodic migraine ≥4 days/month or chronic migraine ≥8 days/month after medication-overuse-headache management, age ≥18 years. Akeega: metastatic BRCA-mutated or suspected BRCA-mutated prostate cancer with prednisone and GnRH therapy. Alecensa/Alunbrig: NSCLC.
    Respiratory, infectious, and neurologic therapies: Prolastin-c requires congenital AAT deficiency, emphysema, conventional emphysema therapy, qualifying genotype, and serum AAT <11 µM/L. Dalfampridine requires MS, walking difficulty, and EDSS ≤7 or no wheelchair restriction. Arformoterol requires COPD maintenance use. Arikayce requires MAC lung disease, combination antibacterial therapy, and inadequate sputum conversion after ≥6 months of multidrug therapy. Augtyro requires ROS1-positive locally advanced/metastatic NSCLC or qualifying NTRK fusion solid tumor with progression or no satisfactory alternatives. Austedo requires Huntington chorea or tardive dyskinesia. Avmapki requires a documented KRAS mutation and prior systemic therapy. Briviact requires partial-onset seizures and age ≥1 month. Bronchitol requires CF, a passed tolerance test, and specialist involvement.
    Oncology and hematology initial pathways: Balversa: locally advanced/metastatic urothelial carcinoma, susceptible FGFR3 alteration, progression after ≥1 systemic therapy, and prior PD-1/PD-L1 therapy or ineligibility. Benlysta: active SLE with ANA ≥1:80 or anti-dsDNA ≥30 IU/mL and standard therapy, or active lupus nephritis with corticosteroid plus mycophenolate/cyclophosphamide; age ≥5 years. Besremi: polycythemia vera with sex-specific hemoglobin/hematocrit threshold, JAK2 mutation or low erythropoietin, and high-risk treatment history when applicable. Bosulif/Danziten: Ph-positive CML. Braftovi: specified melanoma, colorectal cancer, or metastatic NSCLC with BRAF V600 mutation and required combination therapy. Brukinsa, Cabometyx, Calquence, Caplyta, Copiktra, Caprelsa, Cotellic, Cresemba, Ctexli, Cerdelga, Cholbam, and other products require the diagnosis, disease extent, mutation, prior-treatment, combination, and specialist elements stated for the requested indication.
    Inflammatory and immune-mediated pathways: Avtozma requires the applicable RA, GCA, SJIA, PJIA, or SSc-ILD pathway, including two-agent failure/contraindication/intolerance for RA/PJIA, a one-month NSAID trial for SJIA, or qualifying imaging and exclusion of other ILD causes for SSc-ILD. Cosentyx and Actimmune require the applicable plaque psoriasis, PsA, AS, nr-axSpA, ERA, or HS diagnosis, severity/objective inflammation, and topical or NSAID history. Cosentyx IV requires active PsA, AS, or nr-axSpA plus the specified two-agent formulary pathway unless continuation. Enbrel and Humira require indication-specific disease activity and conventional-therapy trials. Inflectra requires qualifying CD/FCD, UC, RA with methotrexate, PsA, plaque psoriasis, AS, or sarcoidosis criteria and the applicable conventional-therapy step.
    Dermatology, asthma, and eosinophilic disease: Dupixent requires the complete indication-specific pathway for eosinophilic or corticosteroid-dependent asthma, CRSwNP, EoE, AD, COPD, bullous pemphigoid, CSU, or AFRS. Ebglyss requires moderate-to-severe AD, age ≥12 years, weight ≥40 kg, BSA ≥10% or SCORAD ≥25, and topical-therapy trial or exception. Emgality requires the requested strength and migraine or cluster-headache threshold/history. Eucrisa requires mild-to-moderate AD and topical corticosteroid trial or sensitive-site exception. Fasenra requires severe eosinophilic asthma with eosinophils ≥150 cells/µL and exacerbation/hospitalization history, or EGPA/HES with the specified steroid, molecular, and eosinophil criteria.
    Other initial pathways: Cialis requires an accepted indication plus alpha-blocker or 5-alpha-reductase-inhibitor contraindication/intolerance and no nitrates. Ciclopirox requires confirmed nail fungus without matrix involvement and the specified terbinafine trial. Cinryze requires confirmed HAE, age ≥6 years, prophylactic use, and no duplicate prophylaxis. Cablivi requires aTTP, IV bolus administration, immunosuppressive therapy, and plasma exchange timing. Roflumilast requires COPD exacerbations and two prior COPD therapies. Metyrosine requires biochemically confirmed pheochromocytoma and the preoperative or chronic-treatment pathway. Diacomit, Doptelet, Dulera, Procrit, Evrysdi, Fabrazyme, Fentanyl, Fintepla, Icatibant, Firmagon, Fotivda, Fruzaqla, Gamastan, Gavreto, growth hormone products, Iclusig, Idhifa, Igalmi, Imbruvica, Imkeldi, Inbrija, Increlex, and other listed products require the exact diagnosis, age, laboratory, specialist, molecular, prior-treatment, or combination requirements summarized in the coverage criteria.

    Reauthorization and Continuation Criteria

    Continuation and reauthorization criteria

    Reauthorization requires continued eligibility and, where stated, documented positive clinical response from baseline. Product-specific restrictions and monitoring continue to apply.

    Continuation of prior therapy: For products whose policy states continuation of prior therapy, the member is continuing the previously authorized drug for the applicable supported indication and remains compliant with any product-specific restrictions.
    Positive response by condition: For rheumatologic disease: reduced swollen/tender joint counts or improved pain, stiffness, inflammation, disease activity, laboratory values, function, or axial status. For psoriasis or AD: reduced BSA, SCORAD, pruritus, or inflammation. For HS: fewer abscesses or inflammatory nodules, fewer new sinus tracts or scars, or symptom improvement. For inflammatory bowel disease: improved mucosal or laboratory inflammation or reversal of high fecal output. For pulmonary disease: improved function, symptoms, exacerbations, or other disease-specific measures. For neurologic disease: improved walking, seizure or motor status, or other indication-specific response. For general specialty drugs: positive clinical response as specified in the product criteria.
    Actimmune and biologic reauthorization: Actimmune reauthorization requires positive clinical response appropriate to the indication. Avtozma requires joint-count, symptom, or disease-specific response. Cosentyx IV requires reduced disease activity or improved clinical measures. Enbrel and Humira require indication-specific improvement from baseline. Dupixent requires positive response plus indication-specific objective improvement or continued concomitant therapy. Ebglyss requires reduced BSA or SCORAD. Fasenra requires positive response for asthma, EGPA, or HES.
    Migraine and headache reauthorization: Aimovig and Emgality require positive response, reduced acute migraine medication use, no prohibited CGRP-inhibitor combination, and continued medication-overuse-headache monitoring for chronic migraine. Episodic cluster-headache Emgality requires positive response and no other injectable CGRP inhibitor.
    Laboratory and disease-monitoring reauthorization: Prolastin-c requires positive response and continued conventional emphysema treatment. Dalfampridine requires improved walking and EDSS ≤7 or no wheelchair restriction. Deferasirox requires reduced ferritin or LIC for transfusional overload/MDS or LIC ≥3 mg Fe/g dw for NTDT. Doptelet ITP requires platelet response sufficient to avoid clinically important bleeding. Procrit requires indication-specific hemoglobin/hematocrit thresholds, positive response, and adequate iron stores where required. Growth hormone therapy requires that expected adult height has not been attained, a documented adult-height goal, and the specified IGF-1 monitoring; PWS requires positive response.
    Safety and combination restrictions: Cinryze and icatibant must not be combined with other approved HAE therapies. Evrysdi must not be combined with chronic SMN-modifying therapy and requires documentation of inadequate response if prior gene therapy was given. Fabrazyme must not be combined with other Fabry drugs. Empaveli primary IC-MPGN continuation requires no kidney transplant and continued ACE inhibitor, ARB, or SGLT2 inhibitor therapy. Emgality and Aimovig retain their CGRP combination restrictions. Epclusa Preferred must not be combined with another HCV direct-acting antiviral.
    Product-specific continuation: Adempas, Bronchitol, Ctexli, Roflumilast, Esbriet, Eucrisa, Inbrija, Increlex, Benlysta, Cholbam, Metyrosine, Fasenra, and other products require positive clinical response. Oncology products including Afinitor, Afinitor Disperz, Akeega, Alecensa, Alunbrig, Augtyro, Avmapki, Ayvakit, Balversa, Besremi, Bosulif, Braftovi, Brukinsa, Cabometyx, Calquence, Caplyta, Caprelsa, Cotellic, Danziten, Daurismo, Diacomit, Ensacove, Epidiolex, Erivedge, Fintepla, Firmagon, Fotivda, Fruzaqla, Gavreto, Ibrance, Iclusig, Idhifa, Imbruvica, Imkeldi, and other listed therapies may be approved for continuation when the underlying indication remains supported.

    Prerequisite and Step-Therapy Requirements

    ProductIndicationRequired prerequisite or prior therapyFailure, contraindication, intolerance, or other requirement
    Afinitor (everolimus tablets)Renal cell carcinomaSUTENT (sunitinib) or NEXAVAR (sorafenib); prerequisite Part D drug requiredTrial and failure, contraindication, or intolerance
    Afinitor (everolimus tablets)Advanced hormone receptor-positive, HER2-negative breast cancerFEMARA (letrozole) or ARIMIDEX (anastrozole); prerequisite Part D drug requiredTrial and failure, contraindication, or intolerance
    AugtyroQualifying ROS1-positive NSCLC or NTRK fusion-positive solid tumorPrerequisite Part D drug requiredFor NTRK tumors, disease must have progressed after prior treatment or have no satisfactory alternative treatment
    Avmapki Fakzynja Co-packKRAS-mutated malignancyPrerequisite Part D drug and prior systemic therapy requiredPrior systemic therapy is required; continuation of prior therapy may be approved
    AvtozmaRheumatoid arthritisPrerequisite Part D therapy; two listed agents or attestation that a trial may be inappropriateTrial and failure, contraindication, or intolerance to two agents, unless continuing prior therapy
    AvtozmaPolyarticular juvenile idiopathic arthritisPrerequisite Part D therapy; two listed agents or attestation that a trial may be inappropriateTrial and failure, contraindication, or intolerance to two agents, unless continuing prior therapy
    AvtozmaSystemic juvenile idiopathic arthritisPrerequisite Part D therapy; maximally tolerated NSAID trialMinimum 1-month NSAID trial
    ActimmuneRheumatoid arthritis, giant cell arteritis, SJIA, PJIA, or SSc-ILDPrerequisite Part D drug requiredFor RA/PJIA, applicable prior-agent requirements apply; for SJIA, a 1-month NSAID trial applies
    AyvakitGIST, advanced systemic mastocytosis, or indolent systemic mastocytosisNo prerequisite Part D drug requiredDisease-specific criteria apply; platelet count must be at least 50 × 10^9/L for systemic mastocytosis
    BalversaLocally advanced or metastatic urothelial carcinomaPrerequisite Part D drug required; at least one prior systemic therapyDisease progression after prior systemic therapy; prior PD-1/PD-L1 therapy or ineligibility required
    BenlystaSLE or lupus nephritisNo prerequisite Part D drug requiredMust be receiving standard-of-care therapy; SLE requires ANA ≥1:80 or anti-dsDNA ≥30 IU/mL
    BesremiPolycythemia veraPrerequisite Part D drug requiredHigh-risk disease requires the stated prior-treatment trial; source criterion is incomplete
    BosulifPhiladelphia chromosome-positive CMLNo prerequisite Part D drug requiredContinuation of prior therapy may be approved
    BraftoviMelanoma or metastatic NSCLCPrerequisite Part D drug required; use with Mektovi (binimetinib)Required BRAF V600E/V600K mutation testing
    BraftoviColorectal cancerPrerequisite Part D drug required; use with Erbitux (cetuximab)Prior therapy or fluorouracil-based chemotherapy required; BRAF V600E mutation required
    BriviactPartial-onset seizuresNo prerequisite Part D drug requiredContinuation of prior therapy may be approved
    BrukinsaMantle cell lymphomaPrerequisite Part D drug requiredAt least one prior therapy
    BrukinsaMarginal zone lymphomaPrerequisite Part D drug requiredRelapsed or refractory disease and at least one prior anti-CD20-based regimen
    BrukinsaFollicular lymphomaPrerequisite Part D drug required; use with GazyvaRelapsed or refractory disease and at least two prior systemic-therapy lines
    CabometyxHepatocellular carcinomaPrerequisite Part D drug required; NexavarTrial and failure, contraindication, or intolerance to Nexavar
    CabometyxDifferentiated thyroid cancerPrerequisite Part D drug required; prior VEGFR-targeted therapyProgression after prior therapy and radioactive-iodine refractory or ineligible disease
    CabometyxPancreatic or extra-pancreatic neuroendocrine tumorsPrerequisite Part D drug required; previous treatmentDisease must be unresectable, locally advanced, or metastatic and well-differentiated
    CalquenceUntreated mantle cell lymphomaPrerequisite Part D drug required; bendamustine and rituximab combinationAutologous HSCT ineligibility required
    CalquencePreviously treated mantle cell lymphomaPrerequisite Part D drug requiredAt least one prior therapy
    CaplytaSchizophreniaPrerequisite Part D drug required; two listed oral generic atypical antipsychoticsTrial and failure, contraindication, or intolerance to both agents
    CaplytaBipolar depressionPrerequisite Part D drug required; quetiapine IR/ER or olanzapineTrial and failure, contraindication, or intolerance
    CaplytaAdjunctive major depressive disorderPrerequisite Part D drug required; aripiprazole and quetiapine IR/ERTrial and failure, contraindication, or intolerance to both agents
    CiclopiroxFingernail onychomycosisPrerequisite Part D drug; oral terbinafineMinimum 6-week supply with trial and failure, contraindication, or intolerance
    CiclopiroxToenail onychomycosisPrerequisite Part D drug; oral terbinafineMinimum 12-week supply with trial and failure, contraindication, or intolerance
    CobenfyMedically accepted indicationsPrerequisite Part D drug; two oral generic formulary atypical antipsychoticsIntolerance to two agents: aripiprazole, asenapine, olanzapine, paliperidone, quetiapine IR/ER, risperidone, or ziprasidone
    CopiktraRelapsed or refractory CLL/SLLPrerequisite Part D drug; at least two prior CLL/SLL therapiesTrial and failure, contraindication, or intolerance
    CosentyxPlaque psoriasisPrerequisite Part D drug; one topical therapyMinimum 4-week trial and failure, contraindication, or intolerance
    CosentyxAnkylosing spondylitisPrerequisite Part D drug; one NSAIDMinimum 1-month trial and failure, contraindication, or intolerance at maximally tolerated dose
    CosentyxNon-radiographic axial spondyloarthritis or ERAPrerequisite Part D drug; two NSAIDsMinimum 1-month trial and failure, contraindication, or intolerance at maximally tolerated doses
    ActimmunePlaque psoriasisPrerequisite Part D drug; one topical corticosteroid, vitamin D analog, tazarotene, or calcineurin inhibitorMinimum 4-week trial with failure, contraindication, or intolerance
    ActimmuneAnkylosing spondylitisPrerequisite Part D drug; one NSAIDMinimum 1-month trial with failure, contraindication, or intolerance at maximally tolerated dose
    ActimmuneNon-radiographic axial spondyloarthritis or ERAPrerequisite Part D drug; two NSAIDsMinimum 1-month trial with failure, contraindication, or intolerance
    Cosentyx IVPsoriatic arthritisTwo listed formulary therapies; prerequisite Part D drug requiredTrial and failure, contraindication, or intolerance, unless continuing prior therapy
    Cosentyx IVAnkylosing spondylitisTwo listed formulary therapies; prerequisite Part D drug requiredTrial and failure, contraindication, or intolerance, unless continuing prior therapy
    Cosentyx IVNon-radiographic axial spondyloarthritisCosentyx SC and Rinvoq; prerequisite Part D drug requiredTrial and failure, contraindication, or intolerance to both, unless continuing prior therapy
    RoflumilastCOPDPrerequisite Part D drug; two prior COPD therapiesTrial and failure, intolerance, or contraindication to both
    MetyrosinePreoperative pheochromocytoma preparationPrerequisite Part D drug; alpha-adrenergic blocker and beta-adrenergic blockerTrial and failure, contraindication, or intolerance to both
    DopteletImmune thrombocytopeniaPrerequisite Part D drug; corticosteroids, immunoglobulins, or splenectomyTrial and failure, contraindication, or intolerance to at least one
    DuleraAsthmaPrerequisite Part D drug; Breo ElliptaIntolerance to Breo Ellipta is referenced in the criteria
    DupixentApplicable covered indicationIndication-specific prerequisite therapy; prerequisite Part D drug requiredMay include asthma controller, intranasal corticosteroid, topical therapy, COPD inhaler regimen, H1 antihistamine, or EoE therapy; contraindication or intolerance may apply
    EbglyssModerate to severe atopic dermatitisMedium- or higher-potency topical corticosteroid or specified alternative; prerequisite Part D drug requiredMinimum 30-day supply, or 14-day supply for topical corticosteroids; trial and failure, contraindication, or intolerance
    EmpaveliC3G or primary IC-MPGNACE inhibitor, ARB, or SGLT2 inhibitor; prerequisite Part D drug requiredMaximally tolerated therapy for at least 12 weeks before initiation and continued when required
    EnbrelRheumatoid arthritisMethotrexate, leflunomide, or sulfasalazine; prerequisite Part D drug requiredMinimum 3-month trial and failure, contraindication, or intolerance
    EnbrelPolyarticular juvenile idiopathic arthritisLeflunomide or methotrexate; prerequisite Part D drug requiredMinimum 6-week trial and failure, contraindication, or intolerance
    EnbrelPlaque psoriasisTopical corticosteroid, vitamin D analog, tazarotene, or calcineurin inhibitor; prerequisite Part D drug required30-day supply, or 14-day supply for topical corticosteroids; failure, contraindication, or intolerance
    EnbrelAnkylosing spondylitisOne NSAID; prerequisite Part D drug requiredMinimum 1-month trial and failure, contraindication, or intolerance at maximally tolerated dose
    EpidiolexLennox-Gastaut syndromeTwo formulary anticonvulsants; prerequisite Part D drug requiredTrial, contraindication, or intolerance to both
    EucrisaMild to moderate atopic dermatitisPrescription-strength topical corticosteroid; prerequisite Part D drug requiredTrial and failure, contraindication, or intolerance, unless affected area is sensitive
    FasenraSevere eosinophilic asthmaAge-appropriate ICS plus additional controller or qualifying ICS/LABA; prerequisite Part D drug requiredCurrent therapy required unless contraindicated or intolerable
    FasenraEGPACorticosteroid therapy; prerequisite Part D drug requiredCurrent therapy required unless contraindicated or intolerable
    FasenraHESCorticosteroid or cytotoxic/immunosuppressive therapy; prerequisite Part D drug requiredFailure, contraindication, or intolerance required
    FruzaqlaMetastatic colorectal cancerFluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy plus anti-VEGF therapy; prerequisite Part D drug requiredRAS-wild-type disease additionally requires anti-EGFR therapy plus Lonsurf or Stivarga
    HumiraRheumatoid arthritisMethotrexate, leflunomide, or sulfasalazineMinimum 3-month trial and failure, contraindication, or intolerance at maximally tolerated doses
    HumiraPolyarticular juvenile idiopathic arthritisLeflunomide or methotrexateMinimum 6-week trial and failure, contraindication, or intolerance at maximally tolerated doses
    HumiraPlaque psoriasisTopical corticosteroid, vitamin D analog, tazarotene, or calcineurin inhibitor30-day supply, or 14-day supply for topical corticosteroids; failure, contraindication, or intolerance
    HumiraAnkylosing spondylitisOne NSAIDMinimum 1-month trial and failure, contraindication, or intolerance at maximally tolerated dose
    HyrnuoLocally advanced or metastatic HER2-mutated non-squamous NSCLCPrior systemic therapy such as chemotherapy; prerequisite Part D drug requiredPrior systemic therapy must be documented
    IgalmiAcute agitation associated with schizophrenia or bipolar I/II disorderAt least two acute-agitation products; prerequisite Part D drug requiredTrial and failure, contraindication, or intolerance to at least two products
    ImbruvicaChronic graft-versus-host diseasePrior systemic therapy; prerequisite Part D drug requiredTrial and failure of one or more lines of systemic therapy
    InbrijaParkinson disease with intermittent OFF episodesTwo of: MAO-B inhibitor, dopamine agonist, or COMT inhibitor; prerequisite Part D drug requiredTrial and failure, contraindication, or intolerance to two classes
    InflectraPlaque psoriasisOne qualifying topical therapy; prerequisite Part D drug requiredMinimum 4-week trial and failure, contraindication, or intolerance
    InflectraCrohn disease, fistulizing Crohn disease, or ulcerative colitisOne qualifying conventional therapy; prerequisite Part D drug requiredTrial and failure, contraindication, or intolerance

    Authorization Duration and Quantity Limits

    Product-specific coverage duration
    ActimmuneInitial coverage 6 months; reauthorization 12 months
    Ayvakit12 months of coverage
    Balversa12 months of coverage
    Benlysta6 months of coverage for initiation and reauthorization
    Besremi12 months of coverage
    Bosulif12 months of coverage
    Braftovi12 months of coverage

    Prior Authorization Submission Requirements

    Prior Authorization

    Obtain prior authorization before dispensing

    Prior authorization is required for each listed product or product group. Submit the indication-specific criteria with the request and note the applicable authorization period; durations range from 4 weeks or 14 days for certain therapies to 6 or 12 months, with continuation generally requiring either continuation of prior therapy or documented positive clinical response.

    • Actimmune injection: prior authorization is required; submit documentation of chronic granulomatous disease or severe malignant osteopetrosis. Coverage is 12 months.
    • Adempas: initial coverage is 6 months and reauthorization is 12 months when the applicable PAH or CTEPH criteria are met.
    • Aimovig: initial coverage is 6 months and reauthorization is 12 months when migraine and response criteria are met.
    • Avtozma: initial coverage is 6 months and reauthorization is 12 months.
    • Bronchitol: initial coverage is 6 months and reauthorization is 12 months.
    • Cresemba: coverage is 6 months; Cyclobenzaprine is 4 weeks for muscle spasm or acute temporomandibular disorder and 12 months for fibromyalgia.
    • Most listed oncology, specialty, biologic, and hematology products have 12-month authorization periods when the applicable criteria are satisfied.
    • Continuation requests must include the applicable prior-therapy continuation information or positive-response evidence when required.
    Step Therapy

    Complete required step therapy first

    Document the required prerequisite therapy, failure, contraindication, or intolerance before requesting the applicable product. The policy uses both product-specific sequencing and indication-specific step therapy; continuation of prior therapy may be an exception where expressly stated.

    • Afinitor: renal cell carcinoma requires prior SUTENT or NEXAVAR failure, contraindication, or intolerance; advanced hormone receptor-positive, HER2-negative breast cancer requires prior FEMARA or ARIMIDEX failure, contraindication, or intolerance.
    • Ciclopirox: require oral terbinafine for at least 6 weeks for fingernail disease or 12 weeks for toenail disease, with failure, contraindication, or intolerance.
    • Actimmune plaque psoriasis: require a minimum 4-week trial of one topical corticosteroid, vitamin D analog, tazarotene, or calcineurin inhibitor, with failure, contraindication, or intolerance.
    • Actimmune ankylosing spondylitis: require a minimum one-month trial of one NSAID at maximally tolerated doses; nr-axSpA and ERA require two NSAIDs for at least one month.
    • Roflumilast: require trial and failure, intolerance, or contraindication to two prior COPD therapies.
    • Metyrosine preoperative preparation: require trial and failure, contraindication, or intolerance to both an alpha-adrenergic blocker and a beta-adrenergic blocker.
    • Doptelet for ITP: require trial and failure, contraindication, or intolerance to corticosteroids, immunoglobulins, or splenectomy.
    • Ebglyss: require at least a 30-day supply of a medium- or higher-potency topical corticosteroid or specified alternative therapy; 14 days applies to topical corticosteroids.
    Documentation Required

    Submit complete clinical documentation

    Submit records that establish the requested indication and every applicable clinical requirement. Depending on the product, this includes laboratory or molecular testing, diagnostic imaging or pathology, disease severity and treatment history, specialist involvement, and baseline-to-follow-up response measures for reauthorization.

    • Diagnosis and disease status: include the confirmed diagnosis, disease extent or severity, qualifying symptoms or clinical findings, and relevant prior treatment history.
    • Laboratory and molecular evidence: submit required values and testing, such as serum AAT, platelet count, eosinophil count, hemoglobin or hematocrit, iron studies, genetic findings, or mutation/rearrangement testing from an FDA-approved or qualifying CLIA laboratory.
    • Diagnostic testing: provide required right-heart catheterization, sputum cultures, KOH preparation, culture or histology, HRCT or biopsy, CYP27A1 testing, or other indication-specific diagnostic results.
    • Specialist qualifications: document prescribing by or consultation with the required specialist, including pulmonology, cardiology, neurology, hematology/oncology, rheumatology, dermatology, gastroenterology, infectious disease, endocrinology, or allergy/immunology as applicable.
    • Response evidence: for reauthorization, submit baseline-to-current measures such as symptom improvement, joint counts, BSA, disease activity, laboratory values, pulmonary exacerbations, platelet response, walking improvement, or other indication-specific positive clinical response.
    Denial Risk

    Avoid common denial triggers

    Requests may be denied when the diagnosis, disease status, prerequisite therapy, laboratory or molecular evidence, specialist requirement, or continuation response is missing or does not meet the applicable criteria. Excluded combinations and uses are not authorized even when the underlying diagnosis is present.

    • Actimmune: coverage is limited to chronic granulomatous disease or severe malignant osteopetrosis; related requests may be denied without required diagnosis, clinical findings, specialist involvement, prerequisite therapy, or positive response.
    • Do not request Cialis with concurrent nitrate use; pyrimethamine for malaria treatment or prophylaxis is not authorized; and metyrosine for essential hypertension is excluded.
    • Do not combine Cinryze with another approved HAE prophylaxis treatment, Epclusa Preferred with another HCV direct-acting antiviral, Emgality with a prohibited CGRP inhibitor combination, or Fabrazyme with another Fabry-disease drug.
    • Ensacove is not supported after prior ALK-inhibitor therapy; Empaveli primary IC-MPGN criteria require no prior kidney transplant; Evrysdi is not covered with concomitant chronic SMN-modifying therapy.
    • Initial requests may be denied when required diagnosis, disease stage, severity, mutation or biomarker testing, age, laboratory threshold, prior therapy, or specialist qualification is absent.
    • Reauthorization may be denied without documented positive clinical response or other indication-specific continuation evidence.

    Clinical Thresholds and Supporting Values

    Operational thresholds
    Aimovig episodic migraineGreater than or equal to 4 migraine days per month
    Aimovig chronic migraineGreater than or equal to 8 migraine days per month
    Prolastin-c pretreatment serum AATLess than 11 µM/L; less than 80 mg/dL by radial immunodiffusion or less than 57 mg/dL by nephelometry
    Dalfampridine EDSS or wheelchair criterionEDSS <= 7, or patient is not restricted to using a wheelchair if EDSS is not measured
    Arikayce sputum conversionAt least two negative sputum cultures after a minimum of 6 consecutive months of multidrug background therapy
    Ayvakit platelet count>= 50 x 10^9/L
    Benlysta minimum age>= 5 years

    Policy Terms and Abbreviations

    Definitions and abbreviations
    Chronic granulomatous disease (CGD)A diagnosis of chronic granulomatous disease.
    Severe malignant osteopetrosis (SMO)A diagnosis of severe malignant osteopetrosis.
    PAHPulmonary arterial hypertension.
    CTEPHChronic thromboembolic pulmonary hypertension.
    SEGA associated with TSCSubependymal giant cell astrocytoma associated with tuberous sclerosis complex.
    TSCTuberous sclerosis complex.
    AAT deficiencyAlpha-1 antitrypsin deficiency.

    Policy Background

    Actimmune (interferon gamma-1b) is covered for two serious inherited disorders: chronic granulomatous disease (CGD) and severe malignant osteopetrosis (SMO). Coverage is based on documented diagnosis; the policy does not specify age or prescriber restrictions for these indications.

    Policy Scope and Administrative Context

    Prior Authorization

    Actimmune requires prior authorization and diagnosis proof

    Prior authorization is required for Actimmune injection. Submit documentation confirming a diagnosis of chronic granulomatous disease or severe malignant osteopetrosis; no age or prescriber restriction is specified, and coverage is authorized for 12 months.

    • Product: Actimmune INJ 100MCG/0.5ML.
    • Covered diagnoses: chronic granulomatous disease (CGD) or severe malignant osteopetrosis (SMO).
    • Continuation of prior Actimmune therapy may be approved.
    Policy Summary
    PayerSanford Health Plan
    PolicyActimmune (S) Prior Authorization Criteria
    Policy CodePolicy 26213
    Change TypeNo material change
    Effective DateSep 1, 2026
    Next Review DateN/A
    Key ActionSubmit documentation confirming chronic granulomatous disease or severe malignant osteopetrosis.
    SourceLink
    On This Page
    Covered Products and Medical Necessity CriteriaInitial Authorization CriteriaReauthorization and Continuation CriteriaPrerequisite and Step-Therapy RequirementsAuthorization Duration and Quantity LimitsPrior Authorization Submission RequirementsClinical Thresholds and Supporting ValuesPolicy Terms and AbbreviationsPolicy BackgroundPolicy Scope and Administrative Context
    Metyrosine is not covered when used to control essential hypertension.
    CGRP combination restriction: Emgality and Aimovig preventive migraine therapy must not be used with another CGRP inhibitor; episodic cluster-headache Emgality must not be used with another injectable CGRP inhibitor.
    Empaveli restriction: For primary IC-MPGN, Empaveli is not covered when the patient has had a kidney transplant.
    Ensacove exclusion: Ensacove initial coverage is not supported after prior treatment with an ALK inhibitor.
    Epclusa Preferred exclusion: Sofosbuvir/velpatasvir is not covered in combination with another HCV direct-acting antiviral.
    Evrysdi exclusion: Evrysdi is not covered with concomitant chronic SMN-modifying therapy for SMA, such as Spinraza.
    Fabrazyme exclusion: Fabrazyme must not be used in combination with another drug used for Fabry disease.
    Icatibant exclusion: Icatibant must not be used with another approved treatment for acute HAE attacks.
    General non-covered requests: Requests lacking the required diagnosis, disease severity or extent, laboratory or molecular confirmation, age, specialist involvement, prior-treatment history, combination regimen, or documented continuation response are not medically necessary under the applicable product criteria.
  1. Enbrel and Humira: indication-specific conventional-therapy trials apply, including 3 months for rheumatoid arthritis, 6 weeks for PJIA, topical therapy for plaque psoriasis, and one month of one NSAID for ankylosing spondylitis.
  2. Epidiolex for Lennox-Gastaut syndrome: require trial of, contraindication to, or intolerance of two formulary anticonvulsants.
  3. Fruzaqla: document prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy plus anti-VEGF therapy, followed by the applicable molecular treatment pathway.
  4. Igalmi, Imbruvica for cGVHD, Inbrija, and Inflectra each require the specified prior treatment history before initial approval.